Evidence map›Paper›PMID 40894807›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025

Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study.

Binbin Fang, Fen Liu, Junyi Luo, Ning Song, Chang Liu, Wei Ji, Xin An, Qian Xie, Yining Yang, Xiaomei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Binbin Fang *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Fen Liu *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Junyi LuoThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Ning SongThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Chang LiuThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Wei JiThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Xin AnThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Qian XieThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Yining YangDepartment of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.ORCID 0000-0002-8332-8508
Xiaomei LiThe First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Data on the effect of GLP-1RA treatment on the long-term prognosis of patients with diabetes after percutaneous coronary intervention (PCI) are scant. The purpose of this study was to evaluate the effect of GLP-1RA treatment on the long-term prognosis in T2DM patients after PCI. Patients and Methods: Data on T2DM patients who underwent PCI from January 2019 to December 2020 were retrospectively analyzed. Clinical data and the use of hypoglycaemic drugs were collected. Patients were divided into 2 groups based on whether they were treated with GLP-1RAs: the control group and the GLP-1RA group. PSM was used to match the control group at a 1:1 ratio. Survival curve and univariate and multivariate Cox regression analyses were used to compare the effects of GLP-1RA treatment on prognosis. Results: A total of 981 patients were enrolled, and 277 pairs (554 patients) were matched with propensity scores. The balance between two groups improved after PSM ( Conclusion: GLP-1RA treatment demonstrates cardiovascular benefits in T2DM patients following PCI, effectively reducing the risk of MACE, and enhancing long-term prognosis.

Indexed as

GLP-1 receptor agonistischemic heart diseaselong-term prognosispercutaneous coronary intervention

Identifiers

PMID40894807
PMCPMC12396521

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.